In the August 2022 issue, an error appeared in Nachawi N, Rao PP, Makin V. The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleve Clin J Med 2022; 89(8):457–464. doi:10.3949/ccjm.89a.21110. In Table 1, the frequency of administration of tirzepatide is once weekly, not once daily. Additional available tirzepatide doses have also been added. The corrected Table 1 appears below:
View this table:
TABLE 1
Glucagon-like peptide-1 receptor agonists approved for use in the United States
This is now correct on ccjm.org.
- Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.